Nice find and thank you for sharing. My hope

Nice find and thank you for sharing.

My hope is that the management stock options (NP - 375,000, MM - 187,500 and NR - 187,500) also awarded yesterday as in lieu of their compensation. Given the low cash balance and timing of the Form 4 filings, it makes sense, but I could not find anything noted in the 10-Q stating such and don't know if they would even need to disclose such information?

I found this excerpt interesting given the recent disclosure of the Samsung commercial grade product timing:

Quote:

---

In addition to the Samsung Agreement, we have also previously entered into an arrangement with another third party contract manufacturer to provide process transfer, validation and manufacturing services for leronlimab. In the event that we terminate the agreement with this manufacturer, we may incur certain financial penalties which would become payable to the manufacturer. Conditioned upon the timing of termination, the financial penalties may total approximately $8.3 million. These amount and timing of the financial commitments under an agreement with our secondary contract manufacturer will depend on the timing of the anticipated approval of our BLA and the initial product demand forecast, which is critical to align the timing of capital resources in order to ensure availability of sufficient quantities of commercial product.

Management believes that two contract manufacturers may best serve our strategic objectives for the anticipated BLA filing and, if approved, the long-term commercial manufacturing capabilities for leronlimab. Management will continue to assess manufacturing capacity requirements as new market information becomes available regarding anticipated demand, subject to FDA approval.

---

Please do your own due diligence. All my posts and comments are not to be considered investment advice.